facts-and-factors.jpg
With 6.10% CAGR, UV Infection Control Device Market Size Worth USD 545.51 Million by 2028: Comprehensive Research Report by Facts & Factors
March 20, 2023 09:32 ET | Facts & Factors
SAN FRANCISCO, U.S., March 20, 2023 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “UV Infection Control Device Market Size, Share, Growth Analysis Report By Type...
FINAL lOGO.png
Driving Growth of Vaginal Antifungals Market by Increasing Prevalence of Vulvovaginal Candidiasis: Persistence Market Research
February 09, 2023 10:40 ET | Persistence Market Research
New York, Feb. 09, 2023 (GLOBE NEWSWIRE) -- The Global Vaginal Antifungals Market was valued at US$ 1 billion in 2021, according to Persistence Market Research’s most recent industry report, and is...
mrf.jpg
Hospital-Acquired Infections Market Size to Hit USD 32.51 Billion by 2030 at 1.37% CAGR – Report by Market Research Future (MRFR)
December 12, 2022 10:00 ET | Market Research Future
New York, USA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Hospital-Acquired Infections Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Hospital Acquired...
logo 600X600.png
Global Hyperbaric Oxygen Therapy (HBOT) Devices Market to Surpass US$ 4,881.5 Million by 2030, Says Coherent Market Insights (CMI)
October 19, 2022 09:35 ET | CMI
Seattle, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global hyperbaric oxygen therapy (HBOT) devices market is estimated to be valued at US$ 2,891.5 million in 2022...
Firm_Logo_November_2020 (2).jpg
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages CorMedix Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – CRMD
July 28, 2021 09:49 ET | The Rosen Law Firm PA
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
UK Doctor Develops ‘MAYA’ (Medical Advice You Access) to Encourage People to Evaluate Their Symptoms and Take Charge of Their Health
January 04, 2021 09:00 ET | AuthorHouse
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- The global outbreak of COVID-19 has sparked a lot of healthcare discussions as many people have avoided seeking medical care to ease the strain on...
aadlogo.jpg
Tips To Avoid Spreading Molluscum Contagiosum; American Academy of Dermatology
December 08, 2020 14:30 ET | American Academy of Dermatology
ROSEMONT, Ill., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Molluscum contagiosum is a common and highly contagious skin condition caused by a virus. According to dermatologists from the American Academy of...
LogoPressRelease.jpg
Fluidigm to Present at Upcoming Health Care Investor Conference
November 10, 2020 08:30 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
rx3000 - manual
Vystar Contracts Partners for Production of Rx3000 UV Light Air Purifiers that Inactivate Airborne Viruses
August 06, 2020 12:54 ET | Vystar Corp.
New manufacturer offers “Made in the USA” expanded production capacity, quality & fast deliveryRx3000® FDA certified Class II Medical device inactivates 99.97% of harmful airborne viruses &...